ReviewFrontiers in immunology2015
The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 72 citations in OpenAlex.
- Single-cell map of innate-like lymphocyte response toiScience · 2025Article
- Comprehensive Insight into the Functional Roles of NK and NKT Cells in HTLV-1-Associated Diseases and Asymptomatic Carriers.Molecular neurobiology · 2024Review
- An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae.Communications biology · 2024Article
- Review
- Context-Dependent Regulation of Type17 Immunity by Microbiota at the Intestinal Barrier.Immune network · 2022Review
- Effective Natural Killer Cell Degranulation Is an Essential Key in COVID-19 Evolution.International journal of molecular sciences · 2022Observational
- Immunomodulatory potential ofiScience · 2022Article
- A therapeutic vaccine strategy to preventFrontiers in immunology · 2022Article
- Roles and therapeutic potential of CD1d-Restricted NKT cells in inflammatory skin diseases.Frontiers in immunology · 2022Review
- Probiotics and Trained Immunity.Biomolecules · 2021Review
- Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases.Clinical microbiology reviews · 2021Review
- Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.PloS one · 2021Article
- Nur77 controls tolerance induction, terminal differentiation, and effector functions in semi-invariant natural killer T cells.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- License to Kill: When iNKT Cells Are Granted the Use of Lethal Cytotoxicity.International journal of molecular sciences · 2020Review
- High Frequency of Gamma Interferon-Producing PLZFJournal of virology · 2020Article
- Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock.Scientific reports · 2020Article
- Clonal enrichments of Vδ2- γδ T cells in Mycobacterium tuberculosis-infected human lungs.The Journal of clinical investigation · 2020Article
- "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.Frontiers in immunology · 2020Review
- Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-ResistantFrontiers in immunology · 2020Article
- Mechanisms of Bacterial Superinfection Post-influenza: A Role for Unconventional T Cells.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Invariant natural killer T (iNKT) cells become activated during a wide variety of infections. This includes organisms lacking cognate CD1d-binding glycolipid antigens recognized by the semi-invariant T cell receptor of iNKT cells. Additional studies have shown that iNKT cells also become activated in vivo in response to microbial products such as bacterial lipopolysaccharide, a potent inducer of cytokine production in antigen-presenting cells (APCs). Other studies have shown that iNKT cells are highly responsive to stimulation by cytokines such as interleukin-12. These findings have led to the concept that microbial pathogens can activate iNKT cells either directly via glycolipids or indirectly by inducing cytokine production in APCs. iNKT cells activated in this manner produce multiple cytokines that can influence the outcome of infection, usually in favor of the host, although potent iNKT cell activation may contribute to an uncontrolled cytokine storm and sepsis. One aspect of the response of iNKT cells to microbial pathogens is that it is short-lived and followed by an extended time period of unresponsiveness to reactivation. This refractory period may represent a means to avoid chronic activation and cytokine production by iNKT cells, thus protecting the host against some of the negative effects of iNKT cell activation, but potentially putting the host at risk for secondary infections. These effects of microbial pathogens and their products on iNKT cells are not only important for understanding the role of these cells in immune responses against infections but also for the development of iNKT cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.